# Michèle Cavo

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/michele-cavo/

## Facts

| Field | Value |
| --- | --- |
| Citations | 71,030 |
| Field | Multiple Myeloma Research and Treatments |
| h-index | 123 |
| i10-index | 571 |
| Last Known Institution | 5T Torino (Italy) |
| OpenAlex ID | https://openalex.org/A5071926851 |
| ORCID iD | https://orcid.org/0000-0003-4514-3227 |
| Works | 1,468 |

## Researcher papers

- [International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma](https://scholariq.org/papers/international-myeloma-working-group-consensus-criteria-for-response-and-minimal/)
- [Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma](https://scholariq.org/papers/idecabtagene-vicleucel-in-relapsed-and-refractory-multiple-myeloma/)
- [Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma](https://scholariq.org/papers/lenalidomide-and-dexamethasone-in-transplant-ineligible-patients-with-myeloma/)
- [Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma](https://scholariq.org/papers/ide-cel-or-standard-regimens-in-relapsed-and-refractory-multiple-myeloma/)
- [Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma](https://scholariq.org/papers/daratumumab-bortezomib-lenalidomide-and-dexamethasone-for-multiple-myeloma/)
- [Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial](https://scholariq.org/papers/pembrolizumab-plus-pomalidomide-and-dexamethasone-for-patients-with-relapsed-or/)
- [LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma](https://scholariq.org/papers/locommotion-a-prospective-non-interventional-multinational-study-of-real-life/)
- [International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation](https://scholariq.org/papers/international-myeloma-working-group-guidelines-for-the-management-of-multiple/)

## Researcher topics

- [Multiple Myeloma Research and Treatments](https://scholariq.org/topics/multiple-myeloma-research-and-treatments/)
- [Protein Degradation and Inhibitors](https://scholariq.org/topics/protein-degradation-and-inhibitors/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [Chronic Myeloid Leukemia Treatments](https://scholariq.org/topics/chronic-myeloid-leukemia-treatments/)
- [Acute Myeloid Leukemia Research](https://scholariq.org/topics/acute-myeloid-leukemia-research/)

## Researcher university

- [5T Torino (Italy)](https://scholariq.org/institutions/5t-torino-italy/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.